cysteamine has been researched along with Degenerative Diseases, Central Nervous System in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Q; Quan, J; Wang, X; Xu, B; Xu, Z | 1 |
| Besouw, M; Levtchenko, E; Masereeuw, R; van den Heuvel, L | 1 |
| Cicchetti, F; Gibrat, C | 1 |
2 review(s) available for cysteamine and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Cysteamine: an old drug with new potential.
Topics: Animals; Cysteamine; Fatty Liver; Humans; Neurodegenerative Diseases; Non-alcoholic Fatty Liver Disease; Radiation-Protective Agents; Randomized Controlled Trials as Topic | 2013 |
Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
Topics: Animals; Cystamine; Cysteamine; Disease Models, Animal; Enzyme Inhibitors; Humans; Huntington Disease; Mice; Mice, Transgenic; Molecular Targeted Therapy; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Radiation-Protective Agents | 2011 |
1 other study(ies) available for cysteamine and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Glutamate-Cysteine Ligase; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Substantia Nigra | 2022 |